A thorough overview of multiple myeloma, including an understanding of treatment options, the importance of patient and doctor communication, and an oncology navigator’s experience treating this form of blood cancer.
At age 24, Nalie Agustin was diagnosed with stage II breast cancer. After about 3 years of remission and gaining a large online following through her inspirational writing, videos, and podcasts, she was diagnosed with metastatic breast cancer. She explains to doctors that their words are as powerful as the treatments they prescribe.
The new cancer drug Tukysa (tucatinib), when given in combination with Herceptin (trastuzumab) and capecitabine, dramatically improved outcomes for patients with HER2-positive advanced breast cancer that has spread to the brain, according to data presented by Nancy U. Lin, MD, Associate Chief, Division of Breast Oncology, Dana-Farber Cancer Institute, Boston, MA, at the 2020 ASCO annual meeting.
Metastatic breast cancer is cancer that has spread beyond the breast to other parts of the body. Visceral metastases refer to cancer that has spread to the internal organs of the body, specifically those within the chest (such as the heart or lungs) or abdomen (such as the liver, pancreas, or intestines).
The combination of Lenvima (lenvatinib), an oral kinase inhibitor, and the immunotherapy Keytruda (pembrolizumab), a PD-1 inhibitor, showed promising benefits for the treatment of patients with liver cancer (or hepatocellular carcinoma) that cannot be removed by surgery (unresectable).
Patients with metastatic (spreading to other parts of the body) non–small-cell lung cancer who received the drug Tecentriq (atezolizumab) as a first-line therapy had improvements in physical functioning, without worsening of their lung cancer–related symptoms, compared with patients who received chemotherapy.
The PARP inhibitor Lynparza (olaparib), a type of drug that is usually used for the treatment of women with ovarian cancer, has also been studied in men with prostate cancer. The results of the PROfound clinical trial were recently presented at the 2020 ASCO annual meeting by Antoine Thiery-Vuillemin, MD, PhD, Centre Hospitalier de Besançon, France.
Results of a new study showed that the combination of Cabometyx (cabozantinib) and the immune checkpoint inhibitor Tecentriq (atezolizumab) was safe and effective in men with metastatic (spreading) castration-resistant prostate cancer, the most common type of prostate cancer.
Studies have shown that adolescent and young adult patients with cancer want to discuss with their doctors sexuality and reproductive health, yet topics such as contraception, body image, and fertility are rarely discussed. Read a doctor’s advice for starting this conversation.
Receiving a breast cancer diagnosis is an overwhelming experience. This article provides answers to questions related to treatment options and finances. Being armed with knowledge can help you take control of your life.
The American Cancer Society guidelines recommend that survivors engage in physical activity at least 150 minutes a week, and follow diets rich in vegetables, fruits, and whole grains, limiting red and processed meats.